William Blair Estimates CVRx’s Q2 Earnings (NASDAQ:CVRX)

CVRx, Inc. (NASDAQ:CVRX) – Equities researchers at William Blair lowered their Q2 2025 earnings per share estimates for shares of CVRx in a research report issued on Wednesday, February 5th. William Blair analyst M. Andrew now forecasts that the company will post earnings of ($0.54) per share for the quarter, down from their prior estimate of ($0.50). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.61) per share. William Blair also issued estimates for CVRx’s Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($2.06) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.92) EPS.

Other analysts have also issued research reports about the company. Craig Hallum increased their price target on CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a report on Friday, January 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $14.00 price target on shares of CVRx in a research note on Wednesday, October 23rd. Canaccord Genuity Group increased their price objective on shares of CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday. Piper Sandler boosted their target price on CVRx from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Lake Street Capital increased their price target on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.83.

CVRx Stock Performance

Shares of CVRX opened at $14.71 on Friday. The company’s fifty day moving average is $14.70 and its 200 day moving average is $11.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 10.23 and a current ratio of 11.32. CVRx has a fifty-two week low of $6.40 and a fifty-two week high of $25.03.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings data on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%.

Hedge Funds Weigh In On CVRx

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its stake in CVRx by 4.5% in the fourth quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company’s stock valued at $385,000 after purchasing an additional 1,296 shares during the last quarter. Calamos Advisors LLC acquired a new stake in shares of CVRx in the 4th quarter worth $134,000. Barclays PLC grew its stake in CVRx by 312.5% during the 3rd quarter. Barclays PLC now owns 19,067 shares of the company’s stock worth $169,000 after buying an additional 14,445 shares during the last quarter. Geode Capital Management LLC raised its stake in CVRx by 2.2% in the third quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock valued at $2,600,000 after buying an additional 6,443 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in CVRx in the third quarter worth about $150,000. Hedge funds and other institutional investors own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.